New oral combo aims to keep devastating blood cancer at bay

NCT ID NCT07463768

Summary

This study is testing whether taking two oral medications, ivosidenib and azacitidine, can help keep a specific type of acute myeloid leukemia (AML) from coming back in older adults. It is for patients aged 55+ who have achieved remission after intensive chemotherapy and have a specific genetic change called an IDH1 mutation. The main goal is to see if this maintenance therapy can help patients stay in remission longer without the need for a stem cell transplant.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CH côte Basque

    Bayonne, 64109, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CH de Perpignan

    Perpignan, 66046, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHRU Nancy

    Vandœuvre-lès-Nancy, 54500, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU Angers

    Angers, 49933, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU Besançon

    Besançon, 25030, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU Grenoble

    Grenoble, 38043, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU Henri Mondor

    Créteil, 94000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU de Limoges

    Limoges, 87000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU de Nantes

    Nantes, 44093, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU de Nîmes - Institut de Cancérologie du Gard

    Nîmes, 30029, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU de TOULOUSE - IUCT ONCOPOLE

    Toulouse, 31059, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Centre Henri Becquerel

    Rouen, 76038, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Chru Bretonneau

    Tours, 37044, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Chru de Lille - Hopital Claude Huriez

    Lille, 59037, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Chu de Rennes - Hopital Pontchaillou

    Rennes, 35033, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Gustave Roussy

    Villejuif, 94800, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hopital d'Instruction des Armées Percy

    Clamart, 92140, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hôpital Haut-Lévêque

    Pessac, 33604, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hôpital Lyon-Sud

    Pierre-Bénite, 69310, France

  • Hôpital Saint Louis

    Paris, 75010, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.